Results 261 to 270 of about 430,220 (382)

Oncological Feasibility of Limited Neck Dissection in cN0 Supraglottic Laryngeal Cancer

open access: yesHead &Neck, EarlyView.
ABSTRACT Background Supraglottic squamous cell carcinoma (SCC) is a significant portion of head and neck cancers, with the management of clinically negative necks (cN0) through selective neck dissection (SND) being debated due to potential morbidities and low metastasis rates in levels IIb and IV.
Sara Bassani   +42 more
wiley   +1 more source

Examining gender trends of conference leadership at the Society of Investigative Dermatology conference, 2018-2023. [PDF]

open access: yesInt J Womens Dermatol
Manjunath J   +5 more
europepmc   +1 more source

Clinico‐Pathological Significance of Tumor Infiltrating Immune Cells in Oral Squamous Cell Carcinoma—Hope or Hype?

open access: yesHead &Neck, EarlyView.
ABSTRACT Background To correlate between immunohistochemical expression of tumor‐infiltrating lymphocytes (TILs), tumor‐associated macrophages (TAMs), and natural killer (NK) cells with the AJCC 8th edition TNM staging system and other disease‐modifying clinico‐pathological variables.
Rajkumar K. Seenivasagam   +10 more
wiley   +1 more source

Oncogenic Human Papillomaviruses Drive One‐Third of Sinonasal Squamous Cell Carcinoma and Are Not Mutually Exclusive for Gene Mutations

open access: yesHead &Neck, EarlyView.
ABSTRACT Background The detection rate of oncogenic human papillomaviruses (HPVs) in sinonasal squamous cell carcinomas (SNSCCs) varies among studies. The mutational landscape of SNSCCs remains poorly investigated. Methods We investigated the prevalence and prognostic significance of HPV infections based on p16 protein expression, HPV‐DNA detection ...
Maxime Henrion   +8 more
wiley   +1 more source

Risk Stratification for Trial Enrichment Considering Loco‐Regional Failure in Head and Neck Cancer: UICC8 Versus Purpose‐Built Failure‐Type Specific Risk Prediction Model

open access: yesHead &Neck, EarlyView.
ABSTRACT Background A previously published failure‐type specific risk model showed good performance in the original cohort. Aim: to validate the model and separate patients with high‐ and low‐risk loco‐regional failure (LRF). Goal: to identify patients potentially suitable for treatment intensification trials. Methods Validation data: 756 patients from
Katrin Håkansson   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy